Abstract
Hepatosplenic T-cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long-term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T-cell leukemia regimen, a nucleoside analog-based consolidation, and allogeneic transplantation associated with GVHD.
Original language | English (US) |
---|---|
Pages (from-to) | 1127-1129 |
Number of pages | 3 |
Journal | Pediatric Blood and Cancer |
Volume | 53 |
Issue number | 6 |
DOIs | |
State | Published - 2009 |
Keywords
- Delta gamma lymphoma
- GVHD
- Hepatosplenic T-cell lymphoma
- Nucleoside analog
- Transplant
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology